Introduction {#s1}
============

Mass cytometry has become a transformative technology for human immune cell profiling. The use of purified metal isotopes as labels for specific antibodies to stain individual cells and detection of these label isotopes on ionized cells by time-of-flight mass spectroscopy allows the analysis of the protein expression of \>40 insightful markers on single cells. The lack of relevant spectral overlap of metal isotopes is a major advantage over traditional fluorescence-based flow cytometry, in which multiplexing of reagents is frequently limited by the need to compensate for overlapping emission spectra of different fluorophores. The ability to integrate the information from more than 40 detection channels for single-cell profiling has been particularly valuable for comprehensive immune monitoring (i.e., analysis of many immune cell lineages) in the setting of translational studies that involve patient cohorts with limited sample access. However, in addition to this "horizontal" profiling approach, mass cytometry also represents a key tool suitable for deep "vertical" profiling of a given immune cell population and may reveal previously unknown heterogeneity within this population, such as complexity within CD8^+^ T cells ([@B1]). In this review, we will discuss how deep immune profiling of exhausted CD8^+^ T cells by mass cytometry has led to significant insights into their heterogeneity and role in pathophysiology across chronic infections and disease. Characterization of exhausted T cells using mass cytometry is of particular relevance in many immuno-oncologic trials that aim to enhance T cell function.

T Cell Exhaustion: Background and Main Concepts {#s2}
===============================================

Exhausted T cells (T~EX~) are increasingly recognized as a distinct T cell population with a key role in many chronic infections and cancer. T~EX~ were initially described in chronic viral infection, and many subsequent reports have highlighted the accumulation of T~EX~ in the context of ongoing bacterial and parasitic infection, as well as cancer and autoimmunity ([@B2]). T~EX~ are characterized by the co-expression of inhibitory receptors and reduced effector function preventing optimal control of viral infection or tumor progression. Targeting inhibitory signaling, such as by interference with inhibitory receptor PD-1 signaling or other immune checkpoints, can reinvigorate T~EX~ function and contribute to disease control or elimination. Consequently, T~EX~ have recently been identified as a major correlate of the clinical response of patients undergoing checkpoint therapy ([@B3], [@B4]), highlighting the need for better immune profiling of T~EX~ as a relevant biomarker for immune therapy trials.

Based on the reduced effector function due to inhibitory signaling in T~EX~ compared to canonical effector T cells (T~EFF~), T~EX~ have been perceived long-term as a population of suppressed effector T cells according to a "loss-of-function" model ([@B5]--[@B7]). However, in recent years, it has become clear that the signals inducing T cell exhaustion following T cell activation can drive these cells dynamically into a distinct differentiation fate compared to T~EFF~ and memory T cells (T~MEM~) that is characterized by massive changes in their metabolism, transcriptome, and epigenome ([@B8]--[@B16]) ([Figure 1](#F1){ref-type="fig"}).

![Model of post-thymic CD8^+^ T cell differentiation. According to this model, after activation of naïve T cells (T~N~) during priming, early activated effector T cells (T~EA~) receive signals driving functional differentiation to effector T cells (T~EFF~) and memory T cells (T~MEM~) depending on the recognition of antigen, costimulation, and the inflammatory milieu. In contrast, persistent antigen stimulation, reduced costimulation in the presence of coinhibitory signals and prolonged exposure to inflammatory cues are main drivers of the differentiation toward the exhausted T cell (T~EX~) fate, including an up-regulation of inhibitory receptors (IRs).](fimmu-10-03039-g0001){#F1}

Exhausted T cells as well as functional effector and memory T cell differentiation are most thoroughly characterized in the Lymphocytic choriomeningitis virus (LCMV) models of acute and chronic viral infection. In these models, genetic differences between acute and chronic LCMV strains are minimal and immunodominant T cell epitopes are identical, facilitating cross-comparison of T cell phenotypes at the level of endogenous responses or by analysis of transferred virus-specific T cells sharing the same T cell receptor. During acute resolving viral infection, viral clearance after induction of functional effector T cells is followed by the establishment of a pool of memory T cells ([@B17], [@B18]) ([Figure 1](#F1){ref-type="fig"}). In sharp contrast, antigen-specific T cells during chronic infection progressively develop major features of exhaustion, including the up-regulation of inhibitory receptor expression and functional impairment (e.g., consecutive loss of IL-2, TNF and IFN-γ production) ([@B6], [@B7], [@B19], [@B20]). While in the first week of chronic infection, the exhaustion program appears to remain flexible and can be altered, as evidenced after transfer of T cells into non-chronically infected hosts, exhaustion appears to become more fixed following the second week of infection ([@B21], [@B22]). Notably, at later time points, the global differentiation program of T~EX~ assessed on the transcriptional and epigenetic level remains stable even after checkpoint blockade intervention and functional reinvigoration ([@B12]).

Challenges for the Assessment of Exhausted T Cells in Humans {#s3}
============================================================

Many insights into T~EX~ have been obtained by the study of antigen-specific T cells in chronic infection and cancer, and multiplexed tetramer analysis together with surface and intracellular markers by mass cytometry has allowed important insights into antigen-specific T cells ([@B1], [@B23]). Identification of T~EX~ without prior knowledge of antigen specificity has remained challenging and is a major obstacle for immune phenotyping in human disease---in particular in cancer---where many tumor antigens especially neoantigens are unknown and tools for assessment of antigen-specific T cell populations are limited. Moreover, established models for T cell differentiation in humans based on markers such as CCR7/CD62L, CD45RA/CD45RO, or CD27/CD28 that allow assessment of naïve T cells (T~N~), T~EFF~, and T~MEM~ and additional subpopulations (e.g., central and effector memory T cells) cannot reliably distinguish T~EX~ from the effector or effector memory T cell phenotype ([@B24]). A likely explanation is that T~EX~, similar to T~EFF~, initially undergo T cell activation programs that include the downregulation of markers of naïvety (such as lymph node homing markers CCR7 and CD62L or preferential CD45RA to CD45RO alternative splicing linked to activation and memory programs), while activation markers, such as CD38 are also induced.

Many investigators have therefore turned to the profiling of inhibitory receptors with a relevant role in T~EX~ biology, such as PD-1 (alone or in combination with other inhibitory receptors such as CTLA-4, Tim-3, Lag-3, 2B4, CD160, TIGIT, and others) for the assessment of exhausted T cells in chronic infections and cancer ([@B20], [@B25]--[@B35]). However, it has become clear that those inhibitory receptors can also be expressed by functional effector T cells and may also be present on memory T cell populations and therefore lack specificity ([@B36]--[@B39]). Moreover, heterogeneous subpopulations of T~EX~ exist for which progenitor-progeny relationships or partial expression of memory-related programs has been described that present further challenges for phenotypic characterization ([@B40]--[@B44]). Nevertheless, while no single phenotypic marker can reliably assess T~EX~ in humans, the utility of combining several inhibitory receptors for the analysis of differences in antigen-specific exhausted T cells suggests that a combinatorial strategy integrating several exhaustion markers might overcome the limitations for immune profiling.

Selection Strategy for Suitable Markers to Identify T~EX~ Using Mass Cytometry {#s4}
==============================================================================

Markers convenient for the identification of T~EX~ and discrimination from T~N~, T~EFF~, and T~MEM~ cells display different levels of expression on T~EX~ compared to these canonical functional T cell populations and across several disease models. To identify such appropriate exhaustion-specific markers, differences in the transcriptional and epigenomic programs between canonical T cell populations and exhausted T cells from the well-controlled LCMV model can be harnessed as specific candidate genes.

Following such an approach, sets of epigenomically regulated exhaustion-specific genes have been recently identified, including 313 genes specifically up-regulated in T~EX~ compared to T~N~, T~EFF~, and T~MEM~ that displayed higher gene expression by transcriptome analysis and concomitant changes in enhancer accessibility ([@B45]). Moreover, 182 genes down-regulated in T~EX~ were identified that were specifically suppressed on a transcriptional level and lacked accessibility of adjacent enhancers. These exhaustion-specific genes identified in the LCMV infection model were thus predicted as sufficient markers of T~EX~. The authors then validated individual genes by comparing them for their enrichment in other murine and human settings of infection and cancer, for which T cell exhaustion has been described. Specific genes for exhaustion-directed immune profiling with strong enrichment of gene expression in multiple settings of exhaustion for which suitable reagents were available for cytometry were then selected for further analysis ([Table 1](#T1){ref-type="table"}).

###### 

Exhaustion markers for T~EX~ profiling.

  **Exhaustion markers**   **Predicted expression vs. T~**N**~ T~**EFF**~ T~**MEM**~**   **Functional role**      **Minimal exhaustion panel**
  ------------------------ ------------------------------------------------------------- ------------------------ ------------------------------
  2B4                      UP                                                            Co-regulatory receptor   X
  Amphiregulin             UP                                                            Cytokine                 
  CCL3                     UP                                                            Chemokine                
  CCR7                     DN                                                            Chemokine receptor       
  CD38                     UP                                                            Ectoenzyme               
  CD39                     UP                                                            Ectoenzyme               X
  CD7                      UP                                                            Co-regulatory receptor   
  CD73                     DN                                                            Ectoenzyme               
  CD127                    DN                                                            Interleukin receptor     X
  CTLA-4                   UP                                                            Co-regulatory receptor   X
  CXCL10                   UP                                                            Chemokine                
  CXCR5                    UP                                                            Chemokine receptor       X
  Eomes                    UP                                                            Transcription factor     X
  Granzyme K               UP                                                            Cytotoxic molecule       
  Helios                   UP                                                            Transcription factor     
  IFN-γ                    ns                                                            Cytokine                 
  IL-2                     DN                                                            Cytokine                 
  IL-10                    UP                                                            Cytokine                 
  IL-21                    UP                                                            Cytokine                 
  Lag-3                    UP                                                            Co-regulatory receptor   
  PD-1                     UP                                                            Co-regulatory receptor   X
  Ptger2                   UP                                                            Prostaglandin receptor   
  TCF1                     DN                                                            Transcription factor     X
  TIGIT                    UP                                                            Co-regulatory receptor   X
  TNF                      ns                                                            Cytokine                 X
  TOX                      UP                                                            Transcription factor     X
  XCL-1                    UP                                                            Chemokine                

*Markers were selected based on exhaustion-specific expression patterns using transcriptomic and epigenomic profiling and validated using mass cytometry. Markers associated with T cell exhaustion, their predicted expression on T~EX~ compared to other cell populations, their functional role as well as their utility for a minimal exhaustion panel is noted. Moreover, cytokines required for the assessment of T~EX~ function are included*.

This approach confirmed several markers of exhausted T cells frequently used for the profiling of T~EX~, such as inhibitory receptors PD-1, 2B4, Lag-3, TIGIT, or transcription factor Eomes. Interestingly, CD38 and CD39, which are also frequently used as activation markers due to their induction on T~EFF~ cells, displayed further exhaustion-specific up-regulation and enhancer changes compared with functional T cell populations. These observations suggest that the interpretation as activation markers indicative for T~EFF~ cells may need to be reevaluated. Furthermore, this analytic approach also identified additional exhaustion markers induced on T~EX~, such as surface proteins CD7, CXCR5, cytotoxic molecule granzyme K or transcription factors Helios and TOX, many of which are also found enriched in tumor-infiltrating lymphocytes by single-cell transcriptomics ([@B46], [@B47]). In agreement with the high levels of TOX on exhausted T cell populations, TOX was recently identified as a master regulator of exhaustion required for the longevity and persistence of exhausted T cells that acts via epigenetic mechanisms facilitating the expression of exhaustion-related gene programs ([@B48], [@B49]). In addition to these novel markers of T~EX~, it has to be noted that other molecules which are also frequently expressed by T~EX~ were not identified as exhaustion-specific candidates by this approach, including inhibitory receptors Tim-3, KLRG1, CD160, or transcription factor T-bet. This was due to lack of significant differences to canonical T cell subsets at the level of gene expression or associated enhancer changes. Similarly, additional immunoregulatory molecules such as CD72 and CD100 which have been previously described as linked to T cell exhaustion have not been identified by this pipeline, suggesting reduced specificity across T cell populations or context-dependent roles ([@B50]). It has to be noted that in this analysis of the specific expression patterns on exhausted cells, individual "exhaustion-specific" molecules can still be expressed to some degree on other T cell subsets (although with a significantly different expression level). Moreover, this strategy also predicted down-regulation of markers associated with naïve and/or memory T cells, such as CCR7, CD73, CD127 and transcription factor TCF-1 on T~EX~ ([Table 1](#T1){ref-type="table"}). The integration of a high number of phenotypic "exhaustion-specific" markers into mass cytometry analysis is expected to allow a better discrimination of T~EX~ populations from T~N~, T~EFF~, or T~MEM~.

Functional Assessment of T~EX~ on a Single-Cell or Population Level {#s5}
===================================================================

Functional impairment is a key characteristic of exhausted T cells. Indeed, the term exhaustion was initially used to describe complete loss of effector function and disappearance of the antigen-specific CD8^+^ T cell response ([@B5], [@B51]). However, it has since become clear that in comparison to functional effector and memory T cells, T~EX~ frequently experience a more gradual loss of effector function that can range from mild impairments in antiviral cytokine production to complete deletion. Typically, mildly exhausted cells exhibit impaired ability to produce IL-2, followed by loss of TNF production in more severe exhaustion, while the ability to produce IFN-γ is frequently maintained and lost usually only in severe exhaustion ([@B52]). Reduced expression of anti-apoptotic molecules (i.e., Bcl2) and higher levels of pro-apoptotic Bim have been reported in T~EX~ and might be linked to a pre-apoptotic phenotype in more severely exhausted cells ([@B53]--[@B55]). Moreover, reduced cytotoxicity and impaired proliferation have been announced for T~EX~, and successful reinvigoration by checkpoint blockade is frequently measured using metrics of cell cycle activity and proliferation ([@B7]). However, it has to be noted that T cell exhaustion is not simply a "loss-of-function" phenotype affecting all T cell functions. On the contrary, higher induction of some chemokines, such as CCL3 and XCL-1, and higher message of other cytokines, such as IL-10 or IL-21, by T~EX~ has been reported ([@B8], [@B45], [@B56]).

Mass cytometry has been instrumental in the comprehensive characterization of T~EX~ function. For example, differences in the cytotoxic program of T~EX~ with an increased expression of granzyme K, but reduced granzyme B and perforin can be readily assessed in combination with phenotypic profiling ([@B57]). Similarly, cell cycle activity assessed by Ki-67 combined with exhaustion marker phenotyping has been pivotal in mass cytometry analysis of responding T~EX~ during checkpoint therapies ([@B3]). Nevertheless, the unbiased per-cell assessment of complex exhaustion-related patterns of impaired cytokine production with phenotypic analysis has remained challenging. For example, analyses focusing on the ability of T cells to express effector cytokines frequently struggle to differentiate between cells that never expressed those molecules (i.e., antigen-naïve T cells) or those that lost expression (including T~EX~). To address these challenges, the characteristic impairment of polyfunctionality with regards to cytokine (e.g., IFN-γ, TNF, IL-2) but increased chemokine production (e.g., CCL3/4, XCL-1) can be used to rate individual T cells for their functional chemokine/cytokine exhaustion profile on a single-cell level using a function-passed exhaustion score. Combined with a comprehensive phenotypic exhaustion profiling possible through the use of mass cytometry, the integration of T~EX~ function as a separate metric of T cell exhaustion was able to reliably discriminate T~EX~ from T~EFF~, T~N~, and T~MEM~ ([@B45]). The combination of high-parametric functional and phenotypic exhaustion profiling may thus represent a helpful tool for the assessment of individual T~EX~ populations but also for the general degree of CD8^+^ T cell immune dysfunction in chronic disease.

Identification of Clinically Relevant High-Dimensional T~EX~ Phenotypes Using Mass Cytometry {#s6}
============================================================================================

The integration of a larger set of exhaustion markers in mass cytometry panels creates novel challenges in data evaluation. In flow cytometry-based studies with few exhaustion markers, data evaluation relies heavily on manual gating and boolean analysis of inhibitory receptor co-expression or polyfunctionality (e.g., using SPICE software analysis) ([@B29], [@B58], [@B59]). These approaches remain valuable for the assessment of T~EX~ using mass cytometry, but have disadvantages compared to bioinformatics algorithm-aided pipelines suitable for the higher data dimensionality generated by mass cytometry. Several bioinformatic strategies have been developed that allow more intuitive visualization of the high-dimensional data using dimension reduction approaches \[most prominently based on visualization of "t stochastic neighborhood embedding," tSNE ([@B60])\], and cluster identification strategies in high-dimensional data \[e.g., SPADE ([@B61]), FlowSOM ([@B62]), PhenoGraph ([@B63]) and many more\] or trajectory inferences that are reviewed elsewhere ([@B64]--[@B66]). For example, tSNE can be used to generate an "exhaustion map" by calculating a two-dimensional representation of the high-dimensional complexity of T~EX~ phenotypes based on exhaustion marker expression ([Figure 2](#F2){ref-type="fig"}). This approach helps in the identification of T~EX~ heterogeneity and points toward differences of the exhaustion landscape in clinical settings ([Figure 2](#F2){ref-type="fig"}), including the detection of specific populations of exhausted T cells enriched in the tumor microenvironment ([@B45]). Moreover, one-dimensional tSNE implementation ("OneSense") has been used to reduce high-dimensional exhaustion phenotypes to a single parameter and compare them with other sets of marker categories (such as "function") ([@B67], [@B68]). However, despite the advantages of tSNE-based analysis and high accuracy regarding local neighborhood relationships, tSNE performs different transformations on different regions of a map, resulting in possible challenges regarding interpretation of distance relationships on a tSNE map. Thus, use of tSNE for the discovery of discrete high-dimensional clusters as a crucial correlate of subsets with distinct biology is challenging. Other dimension reduction strategies with manifold approximation, such as uMAP, may address some of these limitations, but loss of information inherent to dimension-reduction strategies cannot be completely avoided ([@B69]). As a consequence, cluster identification based on the complete high-dimensional data is often preferred. For example, 25 high-dimensional clusters of CD8^+^ T cells were identified using PhenoGraph analysis based on the analysis of exhaustion markers in a large and diverse cohort of patients with chronic HIV infection, lung cancer and healthy controls ([@B45]). These clusters often projected to discrete regions of a tSNE exhaustion map that was calculated using the same exhaustion parameters but also displayed cluster affiliations that were not obvious from a tSNE map ([Figure 2](#F2){ref-type="fig"}). Clearly, such an exhaustion marker-based clustering approach will also identify functional T cells, such as T~N~, T~EFF~, or T~MEM~ cells, but will have increased granularity for T~EX~ subset identification.

![Systems immunology approach for T~EX~ characterization using mass cytometry. Selection of suitable exhaustion markers able to differentiate T~EX~ from T~EFF~ and T~MEM~ such as by transcriptomic or epigenomic profiling is a critical step for T~EX~-directed immune profiling using mass cytometry. High-dimensional analysis of T~EX~ provides further insights into the heterogeneity of T~EX~ that can be unraveled by a bioinformatics pipeline including cluster identification and dimension reduction strategies (i.e., tSNE, Phenograph) that provide detailed overview about the exhaustion landscape. Detailed T~EX~ subset profiling provides the basis for understanding the heterogeneity of T~EX~ and their involvement in different disease settings, such as chronic infection and cancer. Data-driven visualizations in this figure were computed based on a dataset published in Bengsch et al. ([@B12]).](fimmu-10-03039-g0002){#F2}

The characterization of discrete T cell clusters in high-dimensional "exhaustion data space" thus serves as a foundation that requires further detailed analysis of their functional and clinical role. In particular, a combination with functional profiling following short term stimulation is valuable to assess the extent of cellular exhaustion and can be used to determine the single-cell chemokine or cytokine pattern necessary for calculation of a "functional exhaustion score" discussed above. Such a functional profiling combined with a scaffold of phenotypic markers allowed appropriate mapping of chemokine/cytokine functionality to the high-dimensional exhaustion clusters, suggesting that 9--12 of the 25 phenotypically defined discrete CD8^+^ T cell subpopulations fit functional properties of T cell exhaustion ([@B45]).

Several of the identified exhausted clusters enriched in severe disease contexts, such as severe HIV infection with possible AIDS, or in the tumor microenvironment of lung cancer patients. Phenotypically, these disease-associated exhausted T cells displayed co-expression of exhaustion-specific receptors such as PD-1, CD38 and a transcription factor signature characterized by high Eomes and TOX but low TCF-1 expression ([Figure 3](#F3){ref-type="fig"}). Interestingly, disease-associated T~EX~ in chronic infection were further characterized by co-expression of inhibitory receptors TIGIT and 2B4 (as well as some KLRG1 and CD160) while in cancer, T~EX~ more frequently exhibited higher expression of CTLA-4, Lag-3, and CD39. These data suggest a conserved biology of exhausted T cells in chronic infection and cancer but also highlight specific differences in exhaustion programs with potentially large translational relevance. For example, the altered co-expression patterns of immuno-regulatory molecules on different T~EX~ populations across different disease entities or even across different stages of disease suggest that the therapeutic efficacy of combination therapies (i.e., combined targeting of PD-1 and CTLA-4) could vary according to the T~EX~ subset composition. Importantly, not all subsets of functionally exhausted T cells enrich with disease progression. For example, subsets with expression of PD-1 and co-expression of CD127, TCF-1, and CXCR5 were found enriched in HIV patients with relatively good disease control (i.e., high CD4 counts, CD4/CD8 ratio and low viral load) and these "health-associated" T~EX~ subsets were also detected in large amounts in tumor-surrounding macroscopically non-infiltrated lung compared to the tumor tissue.

![Model of T~EX~ heterogeneity and key markers linked to individual subsets. Within the pool of exhausted T cells, three major trajectories of T~EX~ subsets are proposed. Early T~EX~ can give rise to a pool of disease-associated or health-associated T~EX~ that massively differ in their activation program as well as in their transcriptional signature, while between both extremes, a balanced pool of differentiated T~EX~ can be observed. One differentiation trajectory leads to populations with high homeostatic potential that are identified in settings of disease control ("health-associated T~EX~") and can have memory-like features, such as high TCF-1 and CD127 expression. Strong expression of activation markers also found on T~EFF~ cells (e.g., CD38, CD39) and co-expression of many inhibitory receptors (IRs) is a key feature of T~EX~ populations identified in progressive disease in chronic infection and cancer. According to this model, T~EX~ with recent history of activation and severe exhaustion after priming express a different set of IRs (e.g., PD-1, CTLA-4, Lag-3) more frequently observed in cancer compared to highly activated T cells arising in many chronic infections. These highly activated T cells in chronic infection are thought to arise from an intermediate trajectory of T~EX~ (expressing e.g., PD-1, 2B4, TIGIT) after encountering additional antigen stimulation and inhibitory signals. Furthermore, a precursor-progenitor relationship between health- and disease-associated T~EX~ important for cancer immunotherapy has been described, and is indicated by the dotted lines. The different T~EX~ trajectories also reflect differential transcriptional programming by varying T-bet, TCF-1, TOX and Eomes expression.](fimmu-10-03039-g0003){#F3}

These T~EX~ subpopulations identified by high-dimensional analysis using mass cytometry are in agreement with reports about severely exhausted T cells co-expressing several inhibitory receptors being linked to severe disease in chronic infection and cancer in HIV, HCV, HBV, and melanoma patients ([@B29]--[@B32], [@B70]--[@B75]). They are also in agreement with findings of progenitor and progeny relationships within exhausted T cell populations based on PD-1, Eomes and T-bet expression and the enrichment of T~EX~ populations with high homeostatic potential expressing TCF-1 and CD127 in scenarios of disease control (e.g., clearance of HCV infection) ([@B40], [@B44], [@B76]). Moreover, T~EX~ expressing CXCR5 have been linked to better control of HIV infection and are thought to constitute a major subset responding to checkpoint therapy ([@B41], [@B42], [@B77]). Precursor populations of exhausted tumor-infiltrating T cells with higher TCF-1 and CXCR5 expression were also identified to be linked to better clinical outcomes after checkpoint blockade therapy ([@B78]).

Thus, mass cytometry is perfectly suited for the interrogation of the clinically significant T~EX~ heterogeneity. A model of T~EX~ heterogeneity including potential lineage relationships and the suggested markers required for minimal T~EX~ immunoprofiling via mass cytometry is displayed in [Figure 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}.

T~EX~ Profiling by Mass Cytometry: Insights for Checkpoint Therapy Monitoring {#s7}
=============================================================================

T~EX~ are emerging as a central correlate and useful biomarker of successful immune checkpoint blockade therapies. In clinical trials with patients receiving checkpoint therapies, special attention has to be directed to immune-profiling panels, as therapeutic antibodies and staining reagents may compete for the same epitope. While combination stainings with secondary antibodies against the checkpoint reagents are established, these remain to provide challenges for bioinformatic analysis. Moreover, transient permeabilization protocols frequently used for intracellular barcoding in mass cytometry trials can reduce anti-PD-1 staining. Despite these challenges, mass cytometry has been successfully applied in multiple studies profiling CD8^+^ T cells. Reinvigoration of T~EX~ compared to tumor mass was identified as a major correlate of the clinical response of patients with malign melanoma receiving checkpoint therapy with anti-PD-1 antibodies ([@B3]). Similar observations have been made using flow cytometry and in patients with non-small cell lung cancer ([@B4]). In a study comparing the differential effects of PD-1 and CTLA-4 checkpoint therapies, PD-1 blockade was found to preferentially induce a response in the CD8^+^ T~EX~ compartment, while anti-CTLA-4 therapy caused more profound changes in CD4^+^ T cells ([@B79]). These reports also highlight the utility of combining T~EX~-directed panels with markers focusing on other immune cell populations. Indeed, further evidence for the on-treatment role of T~EX~ reinvigoration during anti-PD-1 checkpoint blockade therapies came from a study that also identified a pre-treatment biomarker for checkpoint response on the level of a CD14^+^ CD16^−^ HLA-DR^+^ monocyte population ([@B80]). However, improved and more focused exhaustion-directed profiling of the heterogeneity of T~EX~ subsets will be required for a detailed understanding of T~EX~ dynamics during checkpoint therapies and personalized medicine approaches for combination therapies.

Summary and Outlook {#s8}
===================

The inability to discriminate T~EX~ from T~EFF~ and T~MEM~ using conventional phenotyping approaches has been a longstanding problem, preventing optimal monitoring and understanding of the relevance of T~EX~ in disease. The use of high-parametric mass cytometry has been instrumental in addressing this issue and advanced the characterization of T~EX~. The combinatorial information from several exhaustion markers is required to distinguish T~EX~ from T~EFF~ and T~MEM~ and has also informed our understanding of the heterogeneity of T~EX~. One advantage of mass cytometry---the ability to integrate the higher parametric expression profile of T~EX~ with readouts for functional profiling allows the fine characterization of T~EX~ subpopulations and their involvement in human diseases. Induction of several molecular programs linked to recent T cell activation remains a shared feature of many T~EX~ populations with effector T cells (e.g., CD38, CD39, PD-1), while programs of homeostasis and access to anatomic niches can be shared by other T~EX~ populations (including those linked to disease control) with memory T cells. Heterogeneous T~EX~ subsets with different clinical roles have now been described in several translational settings of human chronic infection and cancer and are implied in differential responsiveness to immune checkpoint blockade.

Other strategies that allow an in-depth profiling of the heterogeneity of exhausted T cell populations have been described, such as scRNA-Seq, which allows the analysis of T cell transcriptomes with single cell resolution. However, currently, these approaches have several limitations over the described mass cytometry approach as they are limited by the limited sensitivity for lowly expressed genes; low cell numbers that can be practically analyzed and therefore limited ability to identify rare populations and limited scaling toward cohort analysis; lack of information on protein expression missing potential post-transcriptional regulation; and, importantly, lack of testing for T cell function. It is further unclear whether excessively larger datasets of mRNA transcripts on a single cell level will reveal more relevant heterogeneity of T~EX~ populations, as the profiling approach outlined above already was designed to maximize utilization of markers informative for differences between T~EX~ and functional T cell subsets. Of note, the combinatorial complexity of high dimensional data generated during immunome analysis by mass cytometry is different from other omics approaches. For example, simultaneous analysis of mass cytometric immune profiling together with transcriptome, microbiome, proteome and metabolome analysis during pregnancy indicated that the mass cytometry dataset was more informative based on modularity analysis (as measured by the number of principal components needed to account for 90% variance of each dataset) compared to the other omics datasets assessing significantly larger numbers of parameters ([@B81]).

To date the most detailed profiling of T~EX~ has been performed in murine models of chronic infection or cancer. With detailed resolution of T~EX~ heterogeneity in humans now accessible through the use of specialized mass cytometry analysis, more detailed identification of T~EX~ features associated with specific types of diseases and anatomical locations that will guide understanding of changes in T~EX~ cell populations in chronic infections, cancer and even autoimmunity is expected. The expression of many exhaustion-related proteins involved in many immuno-regulatory pathways amenable to therapeutic intervention also suggests that T~EX~ profiling might be required for adequate selection of combination therapies and could become indispensable for the rational design of personalized therapeutic treatments.

In sum, deep immune profiling of T~EX~ using mass cytometry is expected to provide further insights into the biology underlying this special T cell differentiation stage and its role in pathogenesis and response to immune therapies in cancer, viral infection and autoimmunity.
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